Atlas FDA

ORTHOVISC SODIUM HYALURONATE

FDA premarket approval P030019/S009 · decided 2007-10-26

Approval details

PMA number
P030019
Supplement
S009
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
ORTHOVISC SODIUM HYALURONATE
Generic name
Acid, hyaluronic, intraarticular
Applicant
Anika Therapeutics, Inc.
Date received
2006-04-28
Decision date
2007-10-26
Days to decision
546 days
Decision code
APPR
Product code
MOZ
Advisory committee
Orthopedic
Expedited review
No
Location
Beford, MA
Statement
APPROVAL FOR MODIFYING THE MANUFACTURING PROCESS FOR ORTHOVISC TO ONE THAT PRODUCES SODIUM HYALURONATE FROM BACTERIAL FERMENTATION. THE DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS (E.G., ACETAMINOPHEN).

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Integrity™ Implant (K250997)Anika Therapeutics, Inc.2025-06-17
Tactoset® Injectable Bone Substitute (K231968)Anika Therapeutics, Inc.2023-12-20
Integrity Implant (K223538)Anika Therapeutics, Inc.2023-08-17
Integrity™ Bone Staple Fixation System (K223860)Anika Therapeutics, Inc.2023-05-22
Anika Tissue Tack Fixation System (K222487)Anika Therapeutics, Inc.2023-05-08
Tactoset (K223915)Anika Therapeutics, Inc.2023-03-29
Tactoset Injectable Bone Substitute (K212083)Anika Therapeutics, Inc.2021-08-31
SCS 17-01 (K190956)Anika Therapeutics, Inc.2020-01-30